RHO and retinitis pigmentosa 1: Targeted inactivation of Nrl via CRISPR/Cas9-mediated genome editing can rescue retinal rod and cone degeneration and restore visual function in four different mouse RP models (rd1, rd10, Rho−/−, RHOP347S)60, 61.